1. Eubacterium hallii et rel. and / or Alcaligenes faecalis et rel. for use in the prevention and / or treatment of insulin resistance and / or complications associated with insulinorezistentnostyu.2. Eubacterium hallii et rel. and / or Alcaligenes faecalis et rel. for use according to Claim. 1, where complications associated with insulin resistance is selected from the metabolic syndrome and dyslipidemia tipa.3 2 diabetes. The pharmaceutical, food or feed composition comprising Eubacterium hallii et rel. and / or Alcaligenes faecalis et rel. for use in the prevention and / or treatment of insulin resistance and / or complications associated with insulinorezistentnostyu.4. Pharmaceutical, food or food composition according to claim. 3, characterized in that said condition associated with insulin resistance is selected from metabolic syndrome, dyslipidemia, and diabetes tipa.5 2. A method for preventing and / or treating insulin resistance and / or complications associated with insulin resistance in a subject if it has need thereof, wherein said method comprises the step of raising Eubacterium hallii et rel. and / or Alcaligenes faecalis et rel. in the small kishechnike.6. The method of claim. 5, characterized in that the level Eubacterium hallii et rel. and / or Alcaligenes faecalis et rel. increases in the small intestine by a method selected from the group consisting of administration of an effective amount of Eubacterium hallii et rel. and / or Alcaligenes faecalis et rel. and introducing to said subject an effective amount of a compound capable of enhancing the level Eubactenum hallii et rel. and / or Alcaligenes faecalis et rel. in the small kishechnike.7. The method of claim. 5 or 6, wherein said conditions associated with insulin resistance is selected from the metabolic syndrome and diabetes dyslipidaemia1. Eubacterium hallii et rel. и/или Alcaligenes faecalis et rel. для применения при профилактике и/или лечении инсулинорезистентности и/или осложнений, связ
